For the quarter ending 2025-12-31, NEUP made $11,493,749 in revenue. $2,434,672 in net income. Net profit margin of 21.18%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Research and development | 697,723 | 3,785,649 | 2,826,023.5 | 1,616,011 |
| General and administrative | 2,126,918 | 1,867,040 | 1,868,729.5 | 1,406,796 |
| Restructuring costs | 1,236,172 | - | - | - |
| Total operating expenses | 4,060,813 | 5,652,689 | 4,694,753 | 3,022,807 |
| License revenue | - | - | -6,633.5 | 15,000,000 |
| Loss from operations | -4,060,813 | -5,652,689 | -4,701,386.5 | 11,977,193 |
| Interest income, net | 167,311 | 141,996 | 61,571 | 12,741 |
| (loss) gain on foreign currency transactions | -135,659 | -61,735 | -608,721.5 | 172,946 |
| Research and development incentive award | -478,959 | - | 550.5 | 5,227 |
| Gain on fair value adjustments | 5,379,500 | -4,368,869 | 205,471 | -976,678 |
| Total other income | 5,890,111 | -4,288,608 | -342,230 | -796,218 |
| Income (loss) before income taxes | 1,829,298 | -9,941,297 | -5,043,616.5 | 11,180,975 |
| Income tax benefit (expense) | -34,794 | -34,793 | -199,394.5 | -81,186 |
| Net income (loss) | 1,864,092 | -9,906,504 | -4,844,222 | 11,262,161 |
| Unrealized gain (loss) on foreign currency translation | 570,580 | 49,221 | 826,390 | -195,818 |
| Total other comprehensive income (loss) | 570,580 | 49,221 | 826,390 | -195,818 |
| Total comprehensive income (loss) | 2,434,672 | -9,857,283 | -4,017,832 | 11,066,343 |
| Earnings per share, basic, total | 0.41 | -4.41 | -2.775 | 6.55 |
| Earnings per share, diluted, total | -0.77 | -4.41 | -2.775 | 6.55 |
| Weighted average shares - basic | 4,536,235 | 2,246,066 | -835,696.5 | 1,719,073 |
| Weighted average shares - diluted | 4,536,235 | 2,246,066 | -835,696.5 | 1,719,073 |
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)